Clinical Trial Update: HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating HPV DNA–guided chemoradiation with or without the PD-1 inhibitor retifanlimab for advanced anal cancer; the study is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Anal Squamous Cell Carcinoma

Drugs mentioned

• Retifanlimab (retifanlimab)

Snippet

Sponsor: Jennifer Dorth | Conditions: Anal Cancer, HPV-Related Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING